Final Exam Flashcards
calcineurin inhibitors MOA
inhibition of calcineurin phosphatase enzyme within T-cell -> inhibits T-cell activiation
cyclosporine target trough
100-400 ng/ml
cyclosporine metabolism
cyp3a4 and p-glycoprotein
cyclosporine adverse effects
- hirsutism
- gingival hyperplasia
- HTN
- Hypertriglyceridemia
- Hypercholesterolemia
which one has a more variable t1/2: cyclosporine or tacrolimus?
cyclosporine
tacrolimus target trough
5-15 ng/ml
tacrolimus metabolism
cyp3a4
tacrolimus adverse effects
- alopeica
- hyperglycemia -> PTDM
- neurotoxicity (insomnia, headache, dizziness)
tacrolimus brand names
- Prograf
- Astagraf XL
- Envarsus XR
cyclosporine brand names
- sandimmune (non-modified)
- Neoral (modified)
- Gengraf (modified)
cyp450 inducers (decrease CSA/FK conc)
- phenytoin
- carbamazepine
- phenobarbital
- rifampin
cyp450 inhibitors (increase CSA/FK conc)
- erithromycin, clarithromycin
- azoles
- diltiazem, verapamil
- ritonavir
- grapefruit juice
Which one alters the PK of CNIs: renal or liver dysfunction?
liver dysfunction
Azathioprine (AZA) MOA
AZA converted to 6-MP which is incorporated into nucleic acids, so RNA and DNA synthesis is inhibited (and therefore immune cell proliferation)
Azathioprine brand name
Imuran
Does AZA require TDM?
No
AZA drug interactions
allopurinol, febuxostat
AZA adverse effects
- GI: N/V/D, pain
- Bone marrow suppression -> anemia, leukopenia, neutropenia, thrombocytopenia
Which antimetabolite is most commonly used in combination with CNIs?
Mycophenolate (usually with tacrolimus)
Mycophenolate MOA
Inhibits de novo synthesis pathway of purine synthesis -> limits progression of activated T and B cells
Mycophenonlate brand names
- Mycophenolate mofetil: CellCept (IR)
- Mycophenolate sodium: Myfortic (DR)
Can mycophenolate be used in pregnancy?
NO - category D/teratogenic
Mycophenolate REMS program
Formal consent for women of childbearing potential - 2 forms of birth control required
Mycophenolate drug interactions
Other myelosuppressive drugs (i.e. valganciclovir, sirolimus) leads to additive myelosuppression